The Role of GLP 1 Receptor Agonists in Treating Heart Failure: Useful or Not? Cover

.blurhash-client-img { display: none !important; }

The Role of GLP 1 Receptor Agonists in Treating Heart Failure: Useful or Not?

Internal Medicine

Volume 21 (2024): Issue 1 (March 2024)

By: Laura Lungeanu-Juravle, Andra Nica, Emilia Rusu and Gabriela Radulian

Open Access

|Mar 2024

Authors

Laura Lungeanu-Juravle

lungeanulaura86@yahoo.com

Department of Cardiology - Clinical Hospital “Nicolae Malaxa”, Bucharest, Romania

Andra Nica

“Carol Davila” University of Medicine and Pharmacy, Bucharest, Romania

Emilia Rusu

“Carol Davila” University of Medicine and Pharmacy, Bucharest, Romania

Gabriela Radulian

“Carol Davila” University of Medicine and Pharmacy, Bucharest, Romania

DOI: https://doi.org/10.2478/inmed-2024-0276 | Journal eISSN: 1220-5818 | Journal ISSN: 1220-5818

Journal RSS Feed

Language: English

Page range: 39 - 47

Published on: Mar 29, 2024

Published by: Romanian Society of Internal Medicine

In partnership with: Paradigm Publishing Services

Publication frequency: 4 issues per year

Keywords:

heart failure (HF),

diabetes mellitus type 2 (T2DM),

Glucagon-like peptide-1 receptor agonists (GLP-1 Ras).

Related subjects:

Clinical medicine,

Internal medicine,

Internal medicine, other,

Gastroenterology,

© 2024 Laura Lungeanu-Juravle, Andra Nica, Emilia Rusu, Gabriela Radulian, published by Romanian Society of Internal Medicine
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 License.

Previous article Volume 21 (2024): Issue 1 (March 2024)Next article